<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><description>佰傲谷致力于打造一个垂直于生物制品领域的第三方平台。为生物制药企业提供品牌推广、技术咨询、项目交易、企业合作、人才培养等服务。为生物制药行业从业人员提供沟通交流、会议培训、工作求职、个人展示平台。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 31 Jan 2021 16:17:40 +0800</pubDate><image><url>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</url><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>靶点药讯46|纵览全球药物靶点动态</title><link>https://mp.weixin.qq.com/s/-oFIFSOzZvfItaMicvjBjA</link><description></description><content:encoded><![CDATA[靶点药讯46|纵览全球药物靶点动态]]></content:encoded><pubDate>Sun, 31 Jan 2021 11:57:56 +0800</pubDate></item><item><title>Nat Immunol:成人和儿童新冠抗体应答不同</title><link>https://mp.weixin.qq.com/s/DaoatrP6Et5MdWgi8LSyVQ</link><description></description><content:encoded><![CDATA[Nat Immunol:成人和儿童新冠抗体应答不同]]></content:encoded><pubDate>Sun, 31 Jan 2021 11:57:56 +0800</pubDate></item><item><title>恒瑞申报第四款ADC药物，“魔法子弹”的竞争早已开始</title><link>https://mp.weixin.qq.com/s/bb2fX0WsGLaYPRXJ924Efg</link><description></description><content:encoded><![CDATA[恒瑞申报第四款ADC药物，“魔法子弹”的竞争早已开始]]></content:encoded><pubDate>Sat, 30 Jan 2021 11:30:57 +0800</pubDate></item><item><title>或将实现“三级跳”，百济神州科创板上市申请获受理</title><link>https://mp.weixin.qq.com/s/6mLasvoDioZsWmbaNZgETw</link><description></description><content:encoded><![CDATA[或将实现“三级跳”，百济神州科创板上市申请获受理]]></content:encoded><pubDate>Sat, 30 Jan 2021 11:30:57 +0800</pubDate></item><item><title>“仅49.4%”，首个新冠南非变异毒株疫苗保护效力公布，来自Novavax</title><link>https://mp.weixin.qq.com/s/0O-SxM_3YWDhN0vtwqfyng</link><description></description><content:encoded><![CDATA[“仅49.4%”，首个新冠南非变异毒株疫苗保护效力公布，来自Novavax]]></content:encoded><pubDate>Fri, 29 Jan 2021 11:48:30 +0800</pubDate></item><item><title>风波叒起，辉瑞JAK抑制剂Ⅳ期临床研究失败</title><link>https://mp.weixin.qq.com/s/KdJA4L2e8fCORdnsUOazRg</link><description></description><content:encoded><![CDATA[风波叒起，辉瑞JAK抑制剂Ⅳ期临床研究失败]]></content:encoded><pubDate>Fri, 29 Jan 2021 11:48:30 +0800</pubDate></item><item><title>一天内4项BD交易，包括礼来、默克等巨头</title><link>https://mp.weixin.qq.com/s/zB_sV_hihslr7WaZM5VLdA</link><description></description><content:encoded><![CDATA[一天内4项BD交易，包括礼来、默克等巨头]]></content:encoded><pubDate>Fri, 29 Jan 2021 11:48:30 +0800</pubDate></item><item><title>偶联抗体好难好费时间？用了这款“傻瓜式”神器，3步解决抗体偶联！</title><link>https://mp.weixin.qq.com/s/z9XQSjTHvHntI8swHGBRtg</link><description></description><content:encoded><![CDATA[偶联抗体好难好费时间？用了这款“傻瓜式”神器，3步解决抗体偶联！]]></content:encoded><pubDate>Thu, 28 Jan 2021 12:15:58 +0800</pubDate></item><item><title>国产PD-1黑马！百济宣布百泽安®食管鳞状细胞癌全球3期临床试验获得积极主要结果</title><link>https://mp.weixin.qq.com/s/U8WuBUPvv_kq5KWNHnwHnA</link><description></description><content:encoded><![CDATA[国产PD-1黑马！百济宣布百泽安®食管鳞状细胞癌全球3期临床试验获得积极主要结果]]></content:encoded><pubDate>Thu, 28 Jan 2021 12:15:58 +0800</pubDate></item><item><title>国内第三家，君实生物抗TIGIT单抗获批临床</title><link>https://mp.weixin.qq.com/s/uzIRrSE3FFhOkdhwpq-04A</link><description></description><content:encoded><![CDATA[国内第三家，君实生物抗TIGIT单抗获批临床]]></content:encoded><pubDate>Thu, 28 Jan 2021 12:15:58 +0800</pubDate></item><item><title>百奥泰贝伐珠单抗生物类似药FDA上市申请获受理</title><link>https://mp.weixin.qq.com/s/HwLbvTaE-KJoui0xSWVL_Q</link><description></description><content:encoded><![CDATA[百奥泰贝伐珠单抗生物类似药FDA上市申请获受理]]></content:encoded><pubDate>Thu, 28 Jan 2021 12:15:58 +0800</pubDate></item><item><title>100%预防新冠肺炎：再生元新冠中和抗体预防新冠病毒感染疗效显著</title><link>https://mp.weixin.qq.com/s/Ertif102wuLivrV522zjkQ</link><description></description><content:encoded><![CDATA[100%预防新冠肺炎：再生元新冠中和抗体预防新冠病毒感染疗效显著]]></content:encoded><pubDate>Wed, 27 Jan 2021 12:23:07 +0800</pubDate></item><item><title>股价下跌4.4%，诺华2020年Q4季度销售业绩不佳</title><link>https://mp.weixin.qq.com/s/EPfyB526uNinMdjNUl3UzQ</link><description></description><content:encoded><![CDATA[股价下跌4.4%，诺华2020年Q4季度销售业绩不佳]]></content:encoded><pubDate>Wed, 27 Jan 2021 12:23:07 +0800</pubDate></item><item><title>“结论明确，不再调查”  中科院回应饶毅举报裴钢论文造假</title><link>https://mp.weixin.qq.com/s/0gWijVuATiA_BAoyfMNJFg</link><description></description><content:encoded><![CDATA[“结论明确，不再调查”  中科院回应饶毅举报裴钢论文造假]]></content:encoded><pubDate>Wed, 27 Jan 2021 12:23:07 +0800</pubDate></item><item><title>ADC治疗晚期非小细胞肺癌HER2基因突变的研究进展</title><link>https://mp.weixin.qq.com/s/RDkafBrJA4dBk_cYTLVrFw</link><description></description><content:encoded><![CDATA[ADC治疗晚期非小细胞肺癌HER2基因突变的研究进展]]></content:encoded><pubDate>Tue, 26 Jan 2021 12:17:45 +0800</pubDate></item><item><title>二次击败阿柏西普，罗氏Ang-2/VEGF-A双抗FaricimabⅢ期临床成功</title><link>https://mp.weixin.qq.com/s/ZGOqEvMU2hcq-rw1UOzN9w</link><description></description><content:encoded><![CDATA[二次击败阿柏西普，罗氏Ang-2/VEGF-A双抗FaricimabⅢ期临床成功]]></content:encoded><pubDate>Tue, 26 Jan 2021 12:17:45 +0800</pubDate></item><item><title>艾伯维新年大礼包，Rinvoq叒获批适应症—PsA、AS</title><link>https://mp.weixin.qq.com/s/fTEhMrEj2qU1ie9QcP4qHA</link><description></description><content:encoded><![CDATA[艾伯维新年大礼包，Rinvoq叒获批适应症—PsA、AS]]></content:encoded><pubDate>Tue, 26 Jan 2021 12:17:45 +0800</pubDate></item><item><title>新冠肺炎累计确诊超“1亿例”</title><link>https://mp.weixin.qq.com/s/imKjJCH6lqjA6IjpcUEMpw</link><description></description><content:encoded><![CDATA[新冠肺炎累计确诊超“1亿例”]]></content:encoded><pubDate>Tue, 26 Jan 2021 12:17:45 +0800</pubDate></item><item><title>复星/BioNTech新冠疫苗復必泰（COMIRNATY）在香港获得紧急使用授权</title><link>https://mp.weixin.qq.com/s/WuAGfu0QfJmurba8kkHPlg</link><description></description><content:encoded><![CDATA[复星/BioNTech新冠疫苗復必泰（COMIRNATY）在香港获得紧急使用授权]]></content:encoded><pubDate>Tue, 26 Jan 2021 12:17:45 +0800</pubDate></item><item><title>《2021版生物制药小编精选文章汇编》发布后记-一场重新开始的旅程</title><link>https://mp.weixin.qq.com/s/15DC3Y1g9ZB6xu_Z1E-oQg</link><description></description><content:encoded><![CDATA[《2021版生物制药小编精选文章汇编》发布后记-一场重新开始的旅程]]></content:encoded><pubDate>Mon, 25 Jan 2021 17:59:45 +0800</pubDate></item></channel></rss>